Darcy Spicer is an Oncology physician affiliated with University of Southern California. OpenAlex indexes 176 publications with 6,723 citations (h-index 35); ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1441 Eastlake Ave
Nor 8302e
Los Angeles, CA 900890112
Telephone
323-865-3105Provider last certified this registry record 28 Aug 2020.
Clinical trials
- Pilot Trial of XFBD, a TCM, in Persons With COVID-19
Sponsor: Darcy Spicer
- Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer
Sponsor: University of Southern California
- Controlled Low Calorie Diet in Reducing Side Effects and Increasing Response to Chemotherapy in Patients With Breast or Prostate Cancer
Sponsor: University of Southern California
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Tempus AI, IncProgram year20251 payment
- Genentech USA, Inc.Program year20221 payment
- Myriad Genetic Laboratories, Inc.Program year20221 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
100%Aromatase Inhibitor100%Anastrozole100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
4 NIH research awards on record, funded 1998–2003 per NIH RePORTER. The latest:
- SCCISARS 2: An e-Solution to Protect Human Subjects
University of Southern California
FY2003$350,000S07RR018274 - PHASE II RANDOMIZED STUDY OF PACLITAXEL VS PACLITAXEL+PSC833 FOR BREAST CANCER
University of Southern California
FY2002M01RR000043 - A PHASE I STUDY OF THE GARFT INHIBITOR AG2034 IN PATIENTS WITH ADVANCED CANCER
University of Southern California
FY2002M01RR000043
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
David Liebeskind, MD
University of Southern California
Lon Schneider, MD
University of Southern California
Amytis Towfighi, MD
University of Southern California
Norah Terrault, MD
University of Southern California
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”